Collectively, these findings established CD4+ T cell loss as a central driver of poor prognosis in HBV+ DLBCL and pointed to the restoration of CD4+ T cell‐mediated immunity as a rational therapeutic strategy with potential clinical impact. The gene discussed is CD4; the disease is diffuse large B-cell lymphoma.